Palliative Konzepte beim Ovarialkarzinom

Kernaussagen

Trotz deutlicher Verbesserungen in der Therapie stirbt die Mehrzahl der Ovarialkarzinompatientinnen an dieser Erkrankung. Das Behandlungsteam muss beim platinrefraktären/platinresistenten OC rechtzeitig den Einsatz wenig wirksamer bzw. unwirksamer Chemotherapien zurücknehmen und stattdessen professionell die sehr beeinträchtigenden Symptome der fortschreitenden OC-Erkrankung hinauszögern bzw. behandeln. Eine enge Kooperation zwischen gynäkologischen Onkologen und Palliativmedizinern ist hierfür die Voraussetzung.

• Literatur

• 1 ECO, European Cancer Observatory. http://
• 2 Lawrie TA, Bryant A, Cameron A et al. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev 2013; (7) CD006910
• 3 Colombo N, Kutarska E, Dimopoulos M et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012; 30: 3841-3847
• 4 Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e.V. und Deutschen Krebshilfe e.V., Hrsg. S3-Leitlinie, Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. München: W. Zuckschwerdt Verlag; 2013
• 5 Hanker LC, Loibl S, Burchardi N et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 2012; 23: 2605-2612
• 6 Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther 2013; 6: 107-118
• 7 Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl. 01) S161-S192
• 8 Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011; 364: 2060-2065
• 9 Peppercorn JM, Smith TJ, Helft PR et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011; 29: 755-760
• 10 Friedlander M, Butow P, Stockler M et al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int Ja Gynecol Cancer 2009; 19 (Suppl. 02) S44-S48
• 11 Emons G. Endokrine Therapie. In: Kreienberg R, du Bois A, Pfisterer J, et al., Hrsg Management des Ovarialkarzinoms. Heidelberg: Springer; 2009: 208-212
• 12 Radwany SM, von Gruenigen VE. Palliative and end-of-life care for patients with ovarian cancer. Clinical Obstet Gynecol 2012; 55: 173-184
• 13 Nappa U, Lindqvist O, Rasmussen BH et al. Palliative chemotherapy during the last month of life. Ann Oncol 2011; 22: 2375-2380
• 14 von Gruenigen VE, Daly BJ. Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 2005; 97: 638-644
• 15 Braga S. Why do our patients get chemotherapy until the end of life?. Ann Oncol 2011; 22: 2345-2348
• 16 Shoemaker LK, Estfan B, Induru R et al. Symptom management: an important part of cancer care. Cleveland Clinic J Med 2011; 78: 25-34
• 17 Klein C, Eckl S, Ostgathe C. Schmerztherapie bei der onkologischen Patientin und in der Palliativmedizin. Frauenheilkunde up2date 2013; 2: 103-118
• 18 Rezk Y, Timmins 3rd PF, Smith HS. Review article: palliative care in gynecologic oncology. Am J Hospice Palliative Care 2011; 28: 356-374
• 19 Mayer-Hope JM, Pothuri B. The role of palliative surgery in gynecologic cancer cases. Oncologist 2013; 18: 73-79
• 20 Pothuri B, Meyer L, Gerardi M et al. Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. Gynecol Oncol 2004; 95: 193-195
• 21 Caceres A, Zhou Q, Iasonos A et al. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. Gynecol Oncol 2008; 108: 482-485
• 22 Pothuri B, Montemarano M, Gerardi M et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 2005; 96: 330-334
• 23 Diver E, OʼConnor O, Garrett L et al. Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecol Oncol 2013; 129: 332-335
• 24 Rath KS, Loseth D, Muscarella P et al. Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer. Gynecol Oncol 2013; 129: 103-106
• 25 Hisanaga T, Shinjo T, Morita T et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Japanese J Clin Oncol 2010; 40: 739-745
• 26 Kucukmetin A, Naik R, Galaal K et al. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst Rev 2010; (7) CD007792
• 27 Leitlinienprogramm Onkologie der AWMF, Deutsche Krebsgesellschaft e. V. und Deutsche Krebshilfe e.V., Hrsg. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. München: W. Zuckschwerdt Verlag; 2012
• 28 Harding V, Fenu E, Medani H et al. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer 2012; 107: 925-930